- Home
- AKBA vs EOI Comparison
AKBA vs EOI Comparison
Compare AKBA & EOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- EOI
- Stock Information
- Founded
- AKBA 2007
- EOI 2004
- Country
- AKBA United States
- EOI United States
- Employees
- AKBA N/A
- EOI N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- EOI Finance/Investors Services
- Sector
- AKBA Health Care
- EOI Finance
- Exchange
- AKBA Nasdaq
- EOI Nasdaq
- Market Cap
- AKBA 958.6M
- EOI 819.4M
- IPO Year
- AKBA 2014
- EOI N/A
- Fundamental
- Price
- AKBA $3.66
- EOI $20.95
- Analyst Decision
- AKBA Strong Buy
- EOI
- Analyst Count
- AKBA 5
- EOI 0
- Target Price
- AKBA $6.90
- EOI N/A
- AVG Volume (30 Days)
- AKBA 3.2M
- EOI 83.6K
- Earning Date
- AKBA 08-07-2025
- EOI 01-01-0001
- Dividend Yield
- AKBA N/A
- EOI 7.19%
- EPS Growth
- AKBA N/A
- EOI N/A
- EPS
- AKBA N/A
- EOI N/A
- Revenue
- AKBA $184,909,000.00
- EOI N/A
- Revenue This Year
- AKBA $26.88
- EOI N/A
- Revenue Next Year
- AKBA $44.34
- EOI N/A
- P/E Ratio
- AKBA N/A
- EOI N/A
- Revenue Growth
- AKBA N/A
- EOI N/A
- 52 Week Low
- AKBA $1.07
- EOI $14.36
- 52 Week High
- AKBA $4.08
- EOI $18.88
- Technical
- Relative Strength Index (RSI)
- AKBA 48.61
- EOI 59.59
- Support Level
- AKBA $3.47
- EOI $20.70
- Resistance Level
- AKBA $4.04
- EOI $21.05
- Average True Range (ATR)
- AKBA 0.17
- EOI 0.19
- MACD
- AKBA -0.06
- EOI -0.02
- Stochastic Oscillator
- AKBA 31.20
- EOI 76.14
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About EOI Eaton Vance Enhance Equity Income Fund Eaton Vance Enhanced Equity Income Fund Shares of Beneficial Interest
Eaton Vance Enhanced Equity Income Fund offers mutual funds that invest across a wide array of equity, income, and alternative strategies. The primary investment objective of the fund is to provide current income, with a secondary objective of capital appreciation.